Scopolamine for Memory Loss
Trial Summary
What is the purpose of this trial?
The goal of this study is to learn about the effects of scopolamine (an anticholinergic drug) on areas of the brain involved in memory, and changes it may have on brain activity. The investigators will do this by testing epileptic patients who are already undergoing intracranial surgery for seizure monitoring, and measuring the activity from the brain areas being assessed. The main questions it aims to answer are 1) whether scopolamine changes memory activity solely at encoding (the time when the person perceives and determines to remember an item or event) as has previously been found, or if it also can selectively impact retrieval (when the item or event which has been processed is recalled or remembered), and 2) what the nature of the brain activity changes is. Participants will complete two treatment arms. One of these will be with the drug, and the other will be with a saline solution, so that the participants are unaware which session the actual drug has been received. Patients will complete a verbal and/or spatial task each of the two days. An anesthesiologist will administer either the drug or the saline at a critical point which addresses both of the research questions. Researchers will compare the brain activity between the two treatment arms to determine what brain activity changes, and at what time point during memory formation.
Do I have to stop taking my current medications for the trial?
The trial information does not specify if you need to stop taking your current medications. However, you should discuss your current medications with the study team to ensure they don't interfere with the trial.
What data supports the effectiveness of the drug Scopolamine for memory loss?
The research indicates that scopolamine can cause temporary memory impairments, which are used as a model to study Alzheimer's disease. However, there is no direct evidence from the provided studies that scopolamine is effective in treating memory loss; instead, it is used to simulate memory deficits for research purposes.12345
How is the drug scopolamine unique for treating memory loss?
Scopolamine is unique because it is administered through a transdermal patch, which provides a steady release of the drug over three days, potentially minimizing side effects compared to oral or injectable forms. It acts as a muscarinic antagonist, which means it blocks certain receptors in the brain, and is being studied for its effects on memory and cognition.14678
Research Team
Bradley Lega, MD
Principal Investigator
University of Texas Southwestern Medical Center
Eligibility Criteria
This trial is for adults aged 18-55 with epilepsy, in good health otherwise, and scheduled for intracranial surgery. They must have a BMI of 18-35 kg/m2 and be able to consent. Excluded are those with significant health issues like heart problems, liver failure, certain neurological conditions, glaucoma, gastrointestinal blockages or pregnant women.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either scopolamine or saline and complete memory tasks
Follow-up
Participants are monitored for memory-related changes in brain electrical activity
Treatment Details
Interventions
- Placebo
- Scopolamine
Scopolamine is already approved in United States, Canada for the following indications:
- Prevention of nausea and vomiting after anesthesia, narcotic pain medicines, and surgery
- Prevention of nausea and vomiting caused by motion sickness
- Prevention of nausea and vomiting after anesthesia, narcotic pain medicines, and surgery
- Prevention of nausea and vomiting caused by motion sickness
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Texas Southwestern Medical Center
Lead Sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Collaborator